Compare BRFH & ATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRFH | ATRA |
|---|---|---|
| Founded | 2005 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 42.7M | 37.6M |
| IPO Year | 2010 | 2014 |
| Metric | BRFH | ATRA |
|---|---|---|
| Price | $2.69 | $5.47 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | $6.00 | $6.00 |
| AVG Volume (30 Days) | 3.8K | ★ 133.6K |
| Earning Date | 05-01-2026 | 04-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.52 | N/A |
| EPS | N/A | ★ 2.93 |
| Revenue | $211,467.00 | ★ $128,940,000.00 |
| Revenue This Year | $37.56 | N/A |
| Revenue Next Year | $101.44 | N/A |
| P/E Ratio | ★ N/A | $1.87 |
| Revenue Growth | 92.09 | ★ 1404.02 |
| 52 Week Low | $2.00 | $3.92 |
| 52 Week High | $6.08 | $19.15 |
| Indicator | BRFH | ATRA |
|---|---|---|
| Relative Strength Index (RSI) | 41.42 | 44.67 |
| Support Level | $2.52 | $4.20 |
| Resistance Level | $3.36 | $5.71 |
| Average True Range (ATR) | 0.11 | 0.46 |
| MACD | -0.01 | 0.40 |
| Stochastic Oscillator | 4.25 | 71.32 |
Barfresh Food Group Inc develops, manufactures and distributes ready to blend frozen beverages, including smoothies, shakes and frappes for restaurant chains and the foodservice industry. The company's proprietary, patented system uses portion-controlled pre-packaged beverage ingredients that deliver freshly made frozen beverages that are quick, cost efficient, and without waste. Barfresh provides both a single serve solution and a bulk format solution, ideal for high-volume locations. It has seven flavors available as part of its standard line vanilla shake, caribbean smoothie, triple berry smoothie, caramel macchiato frappe, strawberry banana smoothie, mocha frappe and mango burst smoothie and has the development capabilities to deliver custom flavors.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).